Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1616 entries
Sorted by: Best Match Show Resources per page
Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF

program design

[No authors listed]
GSID: VYoJUFPmwEIJ
GC Fonarow - Reviews in Cardiovascular Medicine, 2004 - europepmc.org

Patients with heart failure face a very high risk of hospitalizations and mortality. Despite the compelling scientific evidence that angiotensin-converting enzyme inhibitors, beta-blockers …

Cite
Fonarow, G. C. (2004). Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF. Reviews in Cardiovascular Medicine, 5(S1), 45-54.
Fonarow, Gregg C. "Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF." Reviews in Cardiovascular Medicine 5.S1 (2004): 45-54.
Copy Download .nbib Format: MLA
Importance of in-hospital initiation of evidence-based medical therapies for heart failure—a review

program design

Abraham WT, Fonarow GC.
GSID: kVEHjFtsKeMJ
GC Fonarow, M Gheorghiade, WT Abraham - The American journal of …, 2004 - Elsevier

Patients who have had heart failure (HF) face very high risks of hospitalization and mortality. Despite the compelling scientific evidence that angiotensin-converting enzyme inhibitors …

Cite
Fonarow, G. C., Gheorghiade, M., & Abraham, W. T. (2004). Importance of in-hospital initiation of evidence-based medical therapies for heart failure—a review. The American journal of cardiology, 94(9), 1155-1160.
Fonarow, Gregg C., Mihai Gheorghiade, and William T. Abraham. "Importance of in-hospital initiation of evidence-based medical therapies for heart failure—a review." The American journal of cardiology 94.9 (2004): 1155-1160.
Copy Download .nbib Format: MLA
The computer program LUDI: a new method for the de novo design of enzyme inhibitors

program design

[No authors listed]
GSID: rf7xZwDJOW4J
HJ Böhm - Journal of computer-aided molecular design, 1992 - Springer

… the program GRID developed by Goodford [5] calculates binding energies for a given probe (eg carbonyl, amide, aromatic carbon) with a given receptor molecule. In our view this program is a very important first step towards the De...

Cite
Böhm, H. J. (1992). The computer program LUDI: a new method for the de novo design of enzyme inhibitors. Journal of computer-aided molecular design, 6(1), 61-78.
Böhm, Hans-Joachim. "The computer program LUDI: a new method for the de novo design of enzyme inhibitors." Journal of computer-aided molecular design 6.1 (1992): 61-78.
Copy Download .nbib Format: MLA
LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads

program design

[No authors listed]
GSID: SEpmOgI_VbgJ
HJ Böhm - Journal of Computer-Aided Molecular Design, 1992 - Springer

Recent advances in a new method for the de novo design of enzyme inhibitors are reported. A new set of rules to define the possible nonbonded contacts between protein and ligand is …

Cite
Böhm, H. J. (1992). LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. Journal of computer-aided molecular design, 6(6), 593-606.
Böhm, Hans-Joachim. "LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads." Journal of computer-aided molecular design 6.6 (1992): 593-606.
Copy Download .nbib Format: MLA
Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists.

International journal of endocrinology

Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K.
PMID: 23097668
Int J Endocrinol. 2012;2012:519467. doi: 10.1155/2012/519467. Epub 2012 Oct 11.

Aldosterone, a specific mineralocorticoid receptor (MR) agonist and a key player in the development of hypertension, is synthesized as a final product of renin-angiotensin-aldosterone system. Hypertension can be generally treated by negating the effects of angiotensin II through the...

Cite
Ikeda K, Isaka T, Fujioka K, et al. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467doi: 10.1155/2012/519467.
Ikeda, K., Isaka, T., Fujioka, K., Manome, Y., & Tojo, K. (2012). Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. International journal of endocrinology, 2012519467. https://doi.org/10.1155/2012/519467
Ikeda, Keiichi, et al. "Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists." International journal of endocrinology vol. 2012 (2012): 519467. doi: https://doi.org/10.1155/2012/519467
Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467. doi: 10.1155/2012/519467. Epub 2012 Oct 11. PMID: 23097668; PMCID: PMC3477571.
Copy Download .nbib Format: NLM
Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors.

Metabolites

Supuran CT.
PMID: 28926956
Metabolites. 2017 Sep 16;7(3). doi: 10.3390/metabo7030048.

Hypoxia and acidosis are salient features of many tumors, leading to a completely different metabolism compared to normal cells. Two of the simplest metabolic products, protons and bicarbonate, are generated by the catalytic activity of the metalloenzyme carbonic anhydrase...

Cite
Supuran CT. Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors. Metabolites. 2017;7(3)doi: 10.3390/metabo7030048.
Supuran, C. T. (2017). Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors. Metabolites, 7(3), . https://doi.org/10.3390/metabo7030048
Supuran, Claudiu T. "Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors." Metabolites vol. 7,3 (2017). doi: https://doi.org/10.3390/metabo7030048
Supuran CT. Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors. Metabolites. 2017 Sep 16;7(3). doi: 10.3390/metabo7030048. PMID: 28926956; PMCID: PMC5618333.
Copy Download .nbib Format: NLM
Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments.

Nature communications

Becker D, Kaczmarska Z, Arkona C, Schulz R, Tauber C, Wolber G, Hilgenfeld R, Coll M, Rademann J.
PMID: 27677239
Nat Commun. 2016 Sep 28;7:12761. doi: 10.1038/ncomms12761.

Small-molecule fragments binding to biomacromolecules can be starting points for the development of drugs, but are often difficult to detect due to low affinities. Here we present a strategy that identifies protein-binding fragments through their potential to induce the...

Cite
Becker D, Kaczmarska Z, Arkona C, et al. Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments. Nat Commun. 2016;7:12761doi: 10.1038/ncomms12761.
Becker, D., Kaczmarska, Z., Arkona, C., Schulz, R., Tauber, C., Wolber, G., Hilgenfeld, R., Coll, M., & Rademann, J. (2016). Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments. Nature communications, 712761. https://doi.org/10.1038/ncomms12761
Becker, Daniel, et al. "Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments." Nature communications vol. 7 (2016): 12761. doi: https://doi.org/10.1038/ncomms12761
Becker D, Kaczmarska Z, Arkona C, Schulz R, Tauber C, Wolber G, Hilgenfeld R, Coll M, Rademann J. Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments. Nat Commun. 2016 Sep 28;7:12761. doi: 10.1038/ncomms12761. PMID: 27677239; PMCID: PMC5052702.
Copy Download .nbib Format: NLM
Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease.

Case reports in nephrology

Trimarchi H, Canzonieri R, Muryan A, Schiel A, Araoz A, Paulero M, Andrews J, Rengel T, Forrester M, Lombi F, Pomeranz V, Iriarte R, Zotta E.
PMID: 26942026
Case Rep Nephrol. 2016;2016:1492743. doi: 10.1155/2016/1492743. Epub 2016 Jan 28.

No specific or efficient treatment exists for Alport syndrome, an X-linked hereditary disease caused by mutations in collagen type IV, a crucial component of the glomerular basement membrane. Kidney failure is usually a major complication of the disease, and...

Cite
Trimarchi H, Canzonieri R, Muryan A, et al. Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease. Case Rep Nephrol. 2016;2016:1492743doi: 10.1155/2016/1492743.
Trimarchi, H., Canzonieri, R., Muryan, A., Schiel, A., Araoz, A., Paulero, M., Andrews, J., Rengel, T., Forrester, M., Lombi, F., Pomeranz, V., Iriarte, R., & Zotta, E. (2016). Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease. Case reports in nephrology, 20161492743. https://doi.org/10.1155/2016/1492743
Trimarchi, H, et al. "Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease." Case reports in nephrology vol. 2016 (2016): 1492743. doi: https://doi.org/10.1155/2016/1492743
Trimarchi H, Canzonieri R, Muryan A, Schiel A, Araoz A, Paulero M, Andrews J, Rengel T, Forrester M, Lombi F, Pomeranz V, Iriarte R, Zotta E. Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease. Case Rep Nephrol. 2016;2016:1492743. doi: 10.1155/2016/1492743. Epub 2016 Jan 28. PMID: 26942026; PMCID: PMC4749773.
Copy Download .nbib Format: NLM
Sexual dysfunction in patients with multiple sclerosis.

Multiple sclerosis and related disorders

Orasanu B, Frasure H, Wyman A, Mahajan ST.
PMID: 25877633
Mult Scler Relat Disord. 2013 Apr;2(2):117-23. doi: 10.1016/j.msard.2012.10.005. Epub 2012 Nov 30.

BACKGROUND: Sexual dysfunction (SD) is a common complaint in female and male patients with multiple sclerosis (MS) and can arise at anytime during the course of the disease even in patients with low disability. Increasing neurological and physical impairment,...

Cite
Orasanu B, Frasure H, Wyman A, et al. Sexual dysfunction in patients with multiple sclerosis. Mult Scler Relat Disord. 2012;2(2):117-23doi: 10.1016/j.msard.2012.10.005.
Orasanu, B., Frasure, H., Wyman, A., & Mahajan, S. T. (2013). Sexual dysfunction in patients with multiple sclerosis. Multiple sclerosis and related disorders, 2(2), 117-23. https://doi.org/10.1016/j.msard.2012.10.005
Orasanu, Bogdan, et al. "Sexual dysfunction in patients with multiple sclerosis." Multiple sclerosis and related disorders vol. 2,2 (2013): 117-23. doi: https://doi.org/10.1016/j.msard.2012.10.005
Orasanu B, Frasure H, Wyman A, Mahajan ST. Sexual dysfunction in patients with multiple sclerosis. Mult Scler Relat Disord. 2013 Apr;2(2):117-23. doi: 10.1016/j.msard.2012.10.005. Epub 2012 Nov 30. PMID: 25877633.
Copy Download .nbib Format: NLM
[First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction].

Kardiologiia

Kobalava ZD, Pavlikova EP, Averkov OA, Merai I, Babaeva LA, Amirbegishvili IA, Kotovskaya YV, Moiseev VS.
PMID: 28294911
Kardiologiia. 2015 Jul;55(7):14-25.

Simultaneous inhibition of the renin-angiotensin-aldosterone system and the system of degradation of natriuretic peptides can potentially provide unique therapeutic effects in patients with chronic heart failure (CHF) with reduced ejection fraction (EF). Aim of this study was to assess...

Cite
Kobalava ZD, Pavlikova EP, Averkov OA, et al. [First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction]. Kardiologiia. 2015;55(7):14-25
Kobalava, Z. D., Pavlikova, E. P., Averkov, O. A., Merai, I., Babaeva, L. A., Amirbegishvili, I. A., Kotovskaya, Y. V., & Moiseev, V. S. (2015). [First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction]. Kardiologiia, 55(7), 14-25.
Kobalava, Zh D, et al. "[First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction]." Kardiologiia vol. 55,7 (2015): 14-25.
Kobalava ZD, Pavlikova EP, Averkov OA, Merai I, Babaeva LA, Amirbegishvili IA, Kotovskaya YV, Moiseev VS. [First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction]. Kardiologiia. 2015 Jul;55(7):14-25. Russian. PMID: 28294911.
Copy Download .nbib Format: NLM
Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine

Singh G, Manickam A, Sethuraman M, Rathod RC.
PMID: 26816449
Indian J Crit Care Med. 2015 Dec;19(12):731-4. doi: 10.4103/0972-5229.171410.

We describe a case of Takotsubo cardiomyopathy in a case of pituitary macroadenoma in acute adrenal crisis. A 48-year-old man presented with acute onset altered sensorium, vomiting, and gasping. On admission, he was unresponsive and hemodynamically unstable. He was...

Cite
Singh G, Manickam A, Sethuraman M, et al. Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency. Indian J Crit Care Med. 2015;19(12):731-4doi: 10.4103/0972-5229.171410.
Singh, G., Manickam, A., Sethuraman, M., & Rathod, R. C. (2015). Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 19(12), 731-4. https://doi.org/10.4103/0972-5229.171410
Singh, Georgene, et al. "Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency." Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine vol. 19,12 (2015): 731-4. doi: https://doi.org/10.4103/0972-5229.171410
Singh G, Manickam A, Sethuraman M, Rathod RC. Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency. Indian J Crit Care Med. 2015 Dec;19(12):731-4. doi: 10.4103/0972-5229.171410. PMID: 26816449; PMCID: PMC4711208.
Copy Download .nbib Format: NLM
Vascular endothelial dysfunction and pharmacological treatment.

World journal of cardiology

Su JB.
PMID: 26635921
World J Cardiol. 2015 Nov 26;7(11):719-41. doi: 10.4330/wjc.v7.i11.719.

The endothelium exerts multiple actions involving regulation of vascular permeability and tone, coagulation and fibrinolysis, inflammatory and immunological reactions and cell growth. Alterations of one or more such actions may cause vascular endothelial dysfunction. Different risk factors such as...

Cite
Su JB. Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol. 2015;7(11):719-41doi: 10.4330/wjc.v7.i11.719.
Su, J. B. (2015). Vascular endothelial dysfunction and pharmacological treatment. World journal of cardiology, 7(11), 719-41. https://doi.org/10.4330/wjc.v7.i11.719
Su, Jin Bo. "Vascular endothelial dysfunction and pharmacological treatment." World journal of cardiology vol. 7,11 (2015): 719-41. doi: https://doi.org/10.4330/wjc.v7.i11.719
Su JB. Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol. 2015 Nov 26;7(11):719-41. doi: 10.4330/wjc.v7.i11.719. PMID: 26635921; PMCID: PMC4660468.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1616 entries